Comparison
Bremelanotide vs. Teriparatid
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
189691-06-3
52232-67-4
Molecular weight
1025.18 g/mol
4117.8 g/mol
Half-life
2.7 h
1 h
Sequence
Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OHSer-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-PheMechanism of action
Bremelanotide
Bremelanotide is a cyclic peptide that binds non-selectively to melanocortin receptors (MC1R through MC5R) — with highest affinity at MC4R in the central nervous system. The precise role of MC4R activation in sexual behaviour is not fully understood; animal data show effects on hypothalamic circuits. Peripheral effects (blood pressure, hyperpigmentation) are attributed to MC1R/MC2R.
Teriparatid
Teriparatide corresponds to the biologically active first 34 amino acids of human parathyroid hormone and binds the PTH-1 receptor on bone and kidney cells. The literature describes that intermittent receptor activation preferentially stimulates the activity of bone-forming osteoblasts, whereas continuously elevated PTH exposure (as in hyperparathyroidism) tends to favor bone resorption. This time-dependent difference is regarded as the mechanistic basis for the bone-anabolic effect observed in studies.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
5
4
of which in humans
5
4
Effects recorded
3
3
Open conflicts
1
1
Documented adverse events
2
2
Legal status
Full entries
Frequently asked questions
- What is the difference between Bremelanotide and Teriparatid?
- Bremelanotide is classified as "Research other", while Teriparatid is classified as "Research other". Bremelanotide: Synthetic cyclic heptapeptide acting as a non-selective melanocortin-receptor agonist. FDA-approved in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in pre-menopausal women. Teriparatid: Teriparatide is the recombinant N-terminal fragment 1-34 of human parathyroid hormone (PTH). It is regulatory-approved and studied in the scientific literature as a bone-anabolic agent for the treatment of osteoporosis. Unlike antiresorptive agents, studies attribute to it an effect that stimulates new bone formation. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Bremelanotide or Teriparatid?
- The highest available evidence level is "Human RCT" for Bremelanotide and "Human RCT" for Teriparatid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Bremelanotide and Teriparatid in Germany and the United States?
- Germany: Bremelanotide — Unapproved, Teriparatid — Prescription. United States: Bremelanotide — Prescription, Teriparatid — Prescription. These are factual summaries with source and review date on the individual pages.